Illumina Stock Is Up 32% in 2026: Has the GRAIL Recovery Already Been Priced In?

Key Stats for Illumina:

• 52-Week Range: $88.00 to $182.84
• Current Price: $177.65 (as of June 25, 2026 close)
• Market Cap: ~$27 billion
• Street Mean Target: ~$150
• NTM P/E: ~33x
• LTM Gross Margin: 68.3%
• LTM Net Debt/EBITDA: 1.1x
• Q1 2026 Non-GAAP EPS: $1.15 (up 19% year over year)
• Q1 2026 Free Cash Flow: $251 million (up from $208 million)

Most investors never know if a stock is truly undervalued or overpriced. TIKR’s professional-grade valuation tools give you a clear, data-backed answer across 60,000+ stocks for free →

Illumina Earned $5.90 in 2021. Then the GRAIL Acquisition Nearly Wiped It Out

The EPS chart for Illumina, Inc. (ILMN) is one of the more dramatic in large-cap life sciences. Normalized earnings stood at $5.90 in 2021, a strong baseline for a company that had spent nearly two decades building an unassailable position in DNA sequencing. Then Illumina attempted to acquire GRAIL, a cancer detection startup, in a deal that regulators on both sides of the Atlantic ultimately forced it to unwind.

The cost was severe. EPS collapsed to $2.12 in 2022 and then to $0.86 in 2023 as acquisition costs, regulatory battles, and management distraction compressed margins across the business. GRAIL was spun off in June 2024, and the recovery began almost immediately. EPS climbed to $2.45 in 2024 and $4.84 in 2025 as the cost structure normalized and the core sequencing franchise reasserted itself.

Q1 2026 non-GAAP EPS came in at $1.15, up 18.6% year over year and 9% ahead of consensus. Consensus projects continued recovery: around $5.23 in 2026, approaching $5.93 in 2027, and building toward roughly $8.86 by 2030.

The engine driving that recovery is NovaSeq X, Illumina’s flagship high-throughput sequencer. The company placed more than 80 units in Q1, about 20 more than the same quarter a year earlier, and clinical markets now represent over 65% of sequencing consumables revenue.

Clinical sequencing consumables demand grew by 20% (excluding China) for the second consecutive quarter. CEO Jacob Thaysen said that “demand for NovaSeq X is increasing as we help our clinical customers expand into new application areas.”

See the exact moment Wall Street upgrades ILMN stock before the rest of the market piles in — track analyst rating changes in real time with TIKR for free →

Free Cash Flow Fell 88% in 2 Years. It Has Now Fully Recovered

The free cash flow chart tells the same story with different numbers. Illumina generated $891 million in free cash flow in 2021, reflecting a healthy, capital-efficient business at its pre-GRAIL peak. The deal unraveled that quickly: FCF fell to $337 million in 2022 and collapsed to just $106 million in 2023, an 88% decline from the high in two years.

The recovery from there has been sharp. Free cash flow rebounded to $283 million in 2023, jumped to $709 million in 2024, and reached $931 million in 2025, now above the 2021 level. Q1 2026 free cash flow came in at $251 million, up from $208 million a year earlier. The board authorized an additional $1.5 billion in share repurchases in April, a direct signal of confidence in the cash generation trajectory.

The headwinds worth watching are in China, where revenue fell 27.8% year over year in Q1 due to regulatory uncertainty and tariff-related cost pressures, which management flagged as a partial offset to underlying margin gains.

The analyst consensus on Illumina stock is tighter than it looks. Catch the moment targets start moving and ratings shift before the market prices it in. Track ILMN with TIKR for free →

What the TIKR Model Says About Whether the Recovery Is Priced In

This is where the Illumina story gets complicated. The stock has run 32% year-to-date and now sits at $177.65, well above the Street mean target of around $150. The high end of analyst targets is near $185, only about 4% away. Three analysts carry underperform or sell ratings.

The TIKR mid-case model targets around $232, implying roughly 31% total return at about 6% annualized over 4.5 years. That is a modest return for the uncertainty involved, and it depends on around 5% annual revenue growth and net income margins recovering toward 23%. The high case reaches around $371.

The low case lands near $240, still above current levels. The spread between scenarios reflects real uncertainty about how quickly the NovaSeq X installed base converts to recurring consumables revenue and whether China proves temporary or structural.

The honest framing is that the turnaround is real and the numbers validate it. Whether the stock is a buy at current levels depends on whether an investor believes the clinical sequencing opportunity justifies paying 33x forward earnings for a business growing revenue at around 5%.

Should You Invest in Illumina, Inc.?

Illumina’s recovery from the GRAIL episode is one of the cleaner turnaround stories in large-cap biotech over the past two years. Cash generation is back, margins are expanding, and the NovaSeq X platform is gaining clinical traction, creating durable, recurring revenue through consumables.

The difficulty is that the stock has already moved a long way to reflect all of that. At 33x forward earnings, with 5% revenue growth and a Street that is now largely neutral to cautious, the remaining upside requires believing in a long EPS compounding story through 2030. Investors who bought the turnaround earlier are sitting on substantial gains.

Those evaluating a position today are being asked to pay a full price for a recovery that, by most measures, has already happened.

Access Professional Tools to Analyze ILMN stock on TIKR for Free →

Looking for New Opportunities?

• See what stocks billionaire investors are buying so you can follow the smart money.
• Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
• The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!